Elagolix, an FDA-approved gonadotropin-releasing hormone (GnRH) antagonist used for the treatment of endometriosis, was also docked against the selected targets to compare the binding affinities of the phytoconstituents. This evidence concerns the gene GNRH1 and endometriosis.